Skip to content
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Advanced
  • PB2353: HEALTHCARE RESOURCE UT...
  • Cite this
  • Text this
  • Email this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Permanent link
PB2353: HEALTHCARE RESOURCE UTILIZATION AND COSTS OFF THERAPY WITH FIXED-DURATION VENETOCLAX AMONG CLL PATIENTS

PB2353: HEALTHCARE RESOURCE UTILIZATION AND COSTS OFF THERAPY WITH FIXED-DURATION VENETOCLAX AMONG CLL PATIENTS

Bibliographic Details
Main Authors: J. N. Allan, A. P. Skarbnik, N. Emechebe, H. Alhasani, B. S. Manzoor
Format: Article
Language:English
Published: Wiley 2022-06-01
Series:HemaSphere
Online Access:http://journals.lww.com/10.1097/01.HS9.0000852236.17476.58
  • Holdings
  • Description
  • Similar Items
  • Staff View

Internet

http://journals.lww.com/10.1097/01.HS9.0000852236.17476.58

Similar Items

  • 2353
    by: Megan Hoffman, et al.
    Published: (2017-09-01)
  • PB1863: BRUIN CLL-322: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF FIXED DURATION PIRTOBRUTINIB+VENETOCLAX AND RITUXIMAB VS VENETOCLAX AND RITUXIMAB IN PREVIOUSLY TREATED CLL/SLL (TRIAL IN PROGRESS)
    by: A. R. Mato, et al.
    Published: (2022-06-01)
  • PB2353: PROGNOSTIC VALUE OF TIME FROM SYMPTOMS BEGIN TO START TREATMENT IN DIFFUSE LARGE B-CELL LYMPHOMA
    by: Sunil Lakhwani Lakhwani, et al.
    Published: (2023-08-01)
  • PB1878: CROSS-TRIAL ANALYSIS OF FIXED-DURATION IBRUTINIB (I) PLUS VENETOCLAX (V) VS FLUDARABINE (F), CYCLOPHOSPHAMIDE (C), AND RITUXIMAB (R) AS FIRST-LINE TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
    by: J. C. Barrientos, et al.
    Published: (2022-06-01)
  • P670: ABSENCE OF BTK, BCL2, AND PLCG2 MUTATIONS IN RELAPSING CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AFTER FIRST-LINE TREATMENT WITH FIXED-DURATION IBRUTINIB (I) PLUS VENETOCLAX (V)
    by: L. J. Croner, et al.
    Published: (2022-06-01)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs